Retroviral gene therapy vectors and therapeutic methods based thereon

US6544771B1 · kind B1 · utility

Assignees

• Cell Genesys, Inc. · US
• Whitehead Institute For Biomedical Research · US

Inventors

• Isabelle Riviere · Boston, US
• Lawrence K. Cohen · Oakland, US
• Brad Guild · Concord, US
• Lori F. Rafield · Mill Valley, US
• Paul D. Robbins · Upper Nyack, US
• Richard C. Mulligan · Cambridge, US

Key dates

• Filing date: Jun 2, 1994
• Grant date: Apr 8, 2003
• Expiry date: Jun 2, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/13043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.